Torsdag 10 April | 10:04:00 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-12 08:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-10 08:00 Kvartalsrapport 2025-Q2
2025-07-07 N/A X-dag ordinarie utdelning ATORX 0.00 SEK
2025-07-05 N/A Årsstämma
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-04-07 - Split ATORX 1000:1
2025-03-27 - Extra Bolagsstämma 2024
2025-01-22 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning ATORX 0.00 SEK
2024-05-07 - Årsstämma
2024-05-06 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-05-26 - Årsstämma
2023-05-04 - X-dag ordinarie utdelning ATORX 0.00 SEK
2023-04-25 - Kvartalsrapport 2023-Q1
2023-04-14 - Extra Bolagsstämma 2022
2023-02-10 - Bokslutskommuniké 2022
2022-10-20 - Kvartalsrapport 2022-Q3
2022-07-12 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning ATORX 0.00 SEK
2022-05-05 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-11-08 - Extra Bolagsstämma 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-07-13 - Kvartalsrapport 2021-Q2
2021-06-01 - Årsstämma
2021-05-03 - X-dag ordinarie utdelning ATORX 0.00 SEK
2021-04-27 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-07-13 - Kvartalsrapport 2020-Q2
2020-05-06 - X-dag ordinarie utdelning ATORX 0.00 SEK
2020-05-05 - Årsstämma
2020-04-23 - Kvartalsrapport 2020-Q1
2020-02-12 - Bokslutskommuniké 2019
2019-10-24 - Kvartalsrapport 2019-Q3
2019-07-11 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning ATORX 0.00 SEK
2019-05-09 - Årsstämma
2019-04-17 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-12 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning ATORX 0.00 SEK
2018-04-26 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-16 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-03 - X-dag ordinarie utdelning ATORX 0.00 SEK
2017-05-02 - Årsstämma
2017-05-02 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-14 - Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Alligator Bioscience är ett forskningsbaserat bioteknikbolag. Bolaget använder en patenterad teknologi för att utveckla biologiska läkemedelskandidater inom inflammation och cancer, och är verksamt i den tidigare delen av läkemedelsutvecklingskedjan. Alligator Bioscience har en global teknologiplattform och är aktivt inom ett snabbt växande segment på läkemedelsmarknaden – proteinläkemedel. Bolaget grundades år 2001 och har sitt huvudkontor i Lund.
2022-11-01 08:30:00

Lund, Sweden, November 1, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following scientific and industry conferences during November and December 2022:

  • Festival of Biologics, November 2 - 4, Basel, Switzerland
    Mattias Levin, PhD, Senior Team Manager, Antibody Engineering, at Alligator Bioscience, will give a presentation entitled "Neo-X-Prime™: Bispecific Tumor Antigen Conditional CD40 Agonistic Antibodies" at 5:00 pm CET on November 3.

    Registration for the conference is open here.
  • Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, November 8 - 12, Boston, United States
    Malin Lindstedt, visiting professor at Alligator Bioscience and Professor at the Department of Immunotechnology at Lund University, will give a poster presentation entitled “Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody”, poster number 35, on November 10.

    Ana Carneiro, Associate Professor and Consultant at Lund University, will give a poster presentation entitled "ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies", poster number 714, on November 11.

    Registration for the conference is open here.
  • Jefferies 2022 London Healthcare Conference, November 15 - 17, London, United Kingdom
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will attend in person to meet investors.
  • Redeye Life Science Day, November 24, Stockholm, Sweden
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
  • Biostock Life Science Fall Summit 2022, November 29-30, Lund, Sweden
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will give a corporate presentation followed by a Q&A session at 1:00 pm CET on November 30.

    More information about the conference can be viewed here.
  • 13th Annual DNB Nordic Healthcare Conference, December 15, Oslo, Norway
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.

The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on November 1, 2022.